References
1. Yan R, Zhang Y, Li Y, Xia L, Guo Y, Zhou Q. Structural basis for the
recognition of SARS-CoV-2 by full-length human ACE2. Science.
2020;367(6485):1444-8.
2. Lan J, Ge J, Yu J, Shan S, Zhou H, Fan S, et al. Structure of the
SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor.
Nature. 2020; doi: 10.1038/s41586-020-2180-5
3. Guan W,Ni Z, Hu Y, Liang W, Ou C, He J et al. Clinical
characteristics of Coronavirus Disease 2019 in China. N Engl J Med 2020;
doi: 10.1056/NEJMoa2002032
4. Zhang J-j, Dong X, Cao Y-y, Yuan Y-d, Yang Y-b,Yan Y-q et al.
Clinical characteristics of 140 patients infected with SARS CoV-2 in
Wuhan, China. Allergy 2020; doi 10.1111/all.14238
5. Ferguson NM LD, Nedjati-Gilani G, Imai N, Ainslie K, Baguelin M,
Bhatia S et al. Imperial College COVID-19 Response Team. Impact of
non-pharmaceutical interventions (NPIs) to reduce COVID- 19 mortality
and healthcare demand. 2020;
https://www.imperial.ac.uk/media/imperialcollege/medicine/sph/ide/gida-fellowships/Imperial-College-COVID19-NPI-modelling-16-03-2020.pdf
6. Tay MZ, Poh CM, Renia L, MacAry PA,NG LFP. The trinity of Covid-19:
immunity, inflammation, intervention. Nature Rev Immunol 2020 doi
10.1038/s41577-020-0311-8
7. Lythgoe MP, Middleton P. Ongoing clinical trials for the management
of COVID-19 pandemic. Trend in Pharmacol Sci 2020; 20: March.
8. Yang Z, Liu J, Zhou Y, Zhao X, Zhao Q, Liu J. The effect of
corticosteroid treatment on patients with coronavirus infection: a
systematic review and meta-analysis. J Infect 2020; doi
10.1016/j.jinf.2020.03.062 9.Russell B, Moss C, Rigg A, Van Hemerlijck
M. COVID-19 and treatment with NSAIDs and corticiosteroids: should we
limit their use in clinical setting? ecancer 2020;14:1023
10. Halpin DMG, Singh D, Hadfield RM. Inhaled corticosteroids and
COVID-19: a systematic review and clinical perspective. Eur Resp J
2020;doi 10.1183/13993003.01009-2020
11. Bousquet J, Akdis C, Jutel M, Bachert C, Klimek L, Agache I et al.
Intranasal Corticosteroids in Allergic Rhinitis in COVID-19 Infected
Patients: An ARIA-EAACI Statement.Allergy 2020;doi 10.1111/all.14302
12. Feldman M, Maini RN, Woody JN, Holgate ST, Winter G, Rowland M et
al. Trials of anti-tumour necrosis factor therapy for COVID-19 are
urgently needed. Lancet 2020;doi 10.1016/50140-6736(20)30858-8
13. Farag A, Wang P, Ahmed M, Sadek H. identification of FDA approved
drugs targeting COVID-19 virus by structure-based drug repositioning.
Version 2. Chemrxiv 2020; doi 10.26434/chemrxiv.12003930.v2
14. Mullard A. Flooded by the torrent: the COVID-19 drug pipeline.
Lancet 2020;395:1245-6.
15.Cao B, Wang Y, Wen D, Liu W, Wang J, Fan G, et al. A Trial of
Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19. N Engl
J Med. 2020.
16. Grein J, Ohmagari N, Shin D, Diaz G, Asperges E, Castagna A et al.
Compassionate use of Remdesivir for patients with severe COVID-19. N
Engl J Med 2020;DOI:10.1056/NEJMoa2007016
17. Remdesivir in adults with severe COVID-19: a randomised,
double-blind, placebo-controlled, multicentre trial Yeming Wang*, Dingyu
Zhang*, Guanhua Du*, Ronghui Du*, Jianping Zhao*, Yang Jin*, Shouzhi
Fu*, Ling Gao*,Lancet 2020; doi10.1016/ S0140-6736(20)31022-9
18. Thorlund K, Dron L, Park J, Hsu G, Forrest JI, Mills EJ. A real-time
dashboard of clinical trials for COVID-19. Lancet 2020; doi
10.1016/s2589-7500(20)30086-8
19. Bonini S, Eichler HG, Wathion N, Rasi G. Transparency and the
European Medicines Agency–sharing of clinical trial data. N Engl J
Med. 2014;371(26):2452-5.
20. Regulation (EU) no. 536/2014 of the European Parliament and of the
Council of 16 April 2014 on clinical trials on medicinal products for
human use, and repealing Directive 2001/20/EC. Official Journal of the
European Union. 2014.
21. Sim I, Stebbins M, Bierer B, Butte AJ, Drazen J, Dzau V et al. Time
for NIH to lead on data sharing - A draft policy is generally supportive
but should start mandating data sharing. Science 2020; 367 :
1308-9
22. Taichman DB, Backus J, Baethge C, Bauchner H, de Leeuw PW, Drazen
JM, et al. Sharing Clinical Trial Data: A Proposal from the
International Committee of Medical Journal Editors. N Z Med J.
2016;129(1429):7-9.
23. Rome BN, Avorn J. Drug evaluation during the COVID-19 Pandemic. N
Engl J Med 2020; DOI: 10.1056/NEJMMp2009457
24. London AJ, Kimmelman J. Against pandemic research exceptionalism.
Science 2020; 10.1126/science.abc1731
25. Kirkham JJ, Gorst S, Altman DG, Blazeby JM, Clarke M, Tunis S, et
al. Core Outcome Set-STAndardised Protocol Items: the COS-STAP
Statement. Trials. 2019;20(1):116.
26. Hussain A, Bhowmik B, do Vale Moreira NC. COVID-19 and diabetes:
Knowledge in progress. Diabetes Res Clin Pract. 2020;162: doi:
10.1016/j.diabres.2020.108142.
27. Fang L, Karakiulakis G, Roth M. Are patients with hypertension and
diabetes mellitus at increased risk for COVID-19 infection? Lancet
Respir Med 2020 ; doi.org/10.1016/PII
28. Vaduganathan M, Vardeny O, Michel T,McMurray JJV, Pfeffer MA,
Salomon SD. Renin–Angiotensin–Aldosterone System Inhibitors in
Patients with Covid-19. NEJM April8, 2020
29. Siddiqi HK, Mehra MR. COVID-19 Illness in Native and
Immunosuppressed States: A Clinical-Therapeutic Staging Proposal. J
Heart Lung Transplant doi.org/10.1016/j.healun.2020.03.012
30. Kirkham JJ, Davis K, Altman DG, Blazeby JM, Clarke M, Tunis S, et
al. Core Outcome Set-STAndards for Development: The COS-STAD
recommendations. PLoS Med. 2017;14(11):e1002447.
Resources
I.https://www.covid19healthsystem.org/mainpage.aspx